A photo of Trent Hummel.

Co-Medical Director, Brain Tumor Center

Associate Professor, UC Department of Pediatrics

513-803-1140

513-636-3549

Board Certified

My Biography & Research

Biography

Trent R. Hummel, MD, completed his graduate medical training at the University of Cincinnati College of Medicine, residency training in pediatrics at Children's Hospital Medical Center of Akron and pediatric hematology/oncology training at Cincinnati Children's Hospital Medical Center. His current appointment is at Cincinnati Children's Hospital Medical Center within the University of Cincinnati in the capacity of associate professor of pediatrics.

Dr. Hummel's clinical and academic interests pertain to children and families affected by central nervous system tumors. He is a member of the Central Nervous System (Brain Tumor) Committee in the Children's Oncology Group (COG) as well as the Cincinnati Children's co-principal investigator for the Pediatric Brain Tumor Consortium (PBTC). Dr. Hummel focuses on developing novel therapeutics to treat children with all central nervous system tumors including those patients with neurofibromatosis type 1 and 2 related CNS tumors and very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Brain Tumor, Neurofibromatosis, Rasopathy

Research Divisions

Oncology, Cancer and Blood Diseases



Blog Posts

NJoyitAll Camp: Can’t Wait for Another Summer

BlogCancer and Blood Diseases

NJoyitAll Camp: Can’t Wait for Another Summer

By Trent R. Hummel, MD3/13/2019

My Locations

My Education

BS: Eastern Mennonite University, Harrisburg, VA, 1997.

MD: University of Cincinnati College of Medicine, Cincinnati, OH, 2001.

Residency: Children’s Hospital Medical Center of Akron, Akron, OH, 2004.

Fellowship: Pediatric Hematology / Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2007; Research Fellow, Division of Experimental Hematology, Cincinnati Children’s Hospital Medical Center, 2008.

Certification: American Board of Pediatrics, 2004; Pediatrics, 2004; Pediatric Hematology / Oncology, 2011.

My Publications

Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. Lazow, MA; Hoffman, L; Schafer, A; Osorio, DS; Boué, DR; Rush, S; Wright, E; Lane, A; DeWire-Schottmiller, MD; Smolarek, T; et al. Acta Neuropathologica Communications. 2020; 8.

A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). DeWire, M; Fuller, C; Hummel, TR; Chow, LM L; Salloum, R; de Blank, P; Pater, L; Lawson, S; Zhu, X; Dexheimer, P; et al. Journal of Neuro-Oncology. 2020; 149:511-522.

A phase I and pharmacokinetic study of oral dabrafenib in children and adolescent patients with recurrent or refractory BRAF V600 mutation–positive solid tumors. Kieran, MW; Geoerger, B; Dunkel, IJ; Broniscer, A; Hargrave, D; Hingorani, P; Aerts, I; Bertozzi, A; Cohen, KJ; Hummel, TR; et al. Clinical Cancer Research. 2019; 25:7294-7302.

Malignant peripheral nerve sheath tumor: Transformation in a patient with neurofibromatosis type 2. Agresta, L; Salloum, R; Hummel, TR; Ratner, N; Mangano, FT; Fuller, C; McMasters, RL; Pater, L; Jones, BV; Szabo, S; et al. Pediatric Blood and Cancer. 2019; 66:e27520-e27520.

Pediatric intramedullary spinal cord tumor outcomes using the WeeFIM scale. Noh, T; Vogt, MS; Pruitt, DW; Hummel, TR; Mangano, FT. Child's Nervous System. 2018; 34:1753-1758.

Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas. Salloum, R; McConechy, MK; Mikael, LG; Fuller, C; Drissi, R; DeWire, M; Nikbakht, H; De Jay, N; Yang, X; Boue, D; et al. Acta Neuropathologica Communications. 2017; 5.

A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. Dorris, K; Liu, C; Li, D; Hummel, TR; Wang, X; Perentesis, J; Kim, M; Fouladi, M. Pediatric Blood and Cancer. 2017; 64.

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study. Salloum, R; Hummel, TR; Kumar, SS; Dorris, K; Li, S; Lin, T; Daryani, VM; Stewart, CF; Miles, L; Poussaint, TY; et al. Journal of Neuro-Oncology. 2016; 129:443-451.

A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas. Hummel, TR; Salloum, R; Drissi, R; Kumar, S; Sobo, M; Goldman, S; Pai, A; Leach, J; Lane, A; Pruitt, D; et al. Journal of Neuro-Oncology. 2016; 127:53-61.